The ZUMA-3 Trial: Clinical Endpoints

Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.

Related Content:

ZUMA-3: CAR T Therapy for Adult Patients With ALLHematologic Oncology

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation